These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 15365575

  • 1. Combination hormonal therapy: a reassessment within advanced prostate cancer.
    Moul JW, Chodak G.
    Prostate Cancer Prostatic Dis; 2004 Sep; 7 Suppl 1():S2-7. PubMed ID: 15365575
    [Abstract] [Full Text] [Related]

  • 2. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, Fujii M, Takihana Y, Usui T, Matsuda T, Ozono S, Kumon H, Ichikawa T, Miki T, Nonsteroidal Antiandrogen Sequential Alternation for Prostate Cancer Study Group.
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [Abstract] [Full Text] [Related]

  • 3. Endocrine treatment of prostate cancer.
    Tammela T.
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [Abstract] [Full Text] [Related]

  • 4. [Usefulness and positioning of MAB therapy for prostate cancer].
    Akaza H, Chodak GW, Hirao Y.
    Gan To Kagaku Ryoho; 2005 Oct; 32(10):1507-20. PubMed ID: 16227758
    [Abstract] [Full Text] [Related]

  • 5. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
    Calais da Silva FE, Bono AV, Whelan P, Brausi M, Marques Queimadelos A, Martin JA, Kirkali Z, Calais da Silva FM, Robertson C.
    Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
    [Abstract] [Full Text] [Related]

  • 6. Maximal androgen blockade for advanced prostate cancer.
    Klotz L.
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):331-40. PubMed ID: 18471790
    [Abstract] [Full Text] [Related]

  • 7. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
    Sakai H, Igawa T, Tsurusaki T, Yura M, Kusaba Y, Hayashi M, Iwasaki S, Hakariya H, Hara T, Kanetake H.
    Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
    [Abstract] [Full Text] [Related]

  • 8. Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers?
    Bennett CL, Matchar D, McCrory D, McLeod DG, Crawford ED, Hillner BE.
    Cancer; 1996 May 01; 77(9):1854-61. PubMed ID: 8646685
    [Abstract] [Full Text] [Related]

  • 9. [First line therapy in the treatment of metastatic prostate cancer].
    Sakai H, Kanetake H.
    Gan To Kagaku Ryoho; 2003 Jan 01; 30(1):43-9. PubMed ID: 12557704
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Risks and benefits of hormonal manipulation as monotherapy or adjuvant treatment in localised prostate cancer.
    Abrahamsson PA, Anderson J, Boccon-Gibod L, Schulman C, Studer UE, Wirth M.
    Eur Urol; 2005 Dec 01; 48(6):900-5. PubMed ID: 16257109
    [Abstract] [Full Text] [Related]

  • 12. [Maximal androgen blockade in the treatment of patients with disseminated cancer of the prostate].
    Matveev BP, Bukharkin BV.
    Vopr Onkol; 1998 Dec 01; 44(5):537-40. PubMed ID: 9884710
    [Abstract] [Full Text] [Related]

  • 13. [Radiotherapy combined with hormonal therapy as treatment method in patients with prostate cancer: still more questions than answers].
    Milecki P.
    Przegl Lek; 2005 Dec 01; 62(12):1455-9. PubMed ID: 16786772
    [Abstract] [Full Text] [Related]

  • 14. Management of locally advanced prostate cancer: a European consensus.
    Boccon-Gibod L, Bertaccini A, Bono AV, Dev Sarmah B, Höltl W, Mottet N, Tunn U, Zamboglou N.
    Int J Clin Pract; 2003 Apr 01; 57(3):187-94. PubMed ID: 12723722
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Endocrine therapy for prostate cancer.
    Damber JE.
    Acta Oncol; 2005 Apr 01; 44(6):605-9. PubMed ID: 16165920
    [Abstract] [Full Text] [Related]

  • 18. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR, CaPSURE Investigators.
    Cancer; 2006 Apr 15; 106(8):1708-14. PubMed ID: 16544313
    [Abstract] [Full Text] [Related]

  • 19. [Hormonal therapy for prostatic cancer--state of the art].
    Miyakita H.
    Nihon Rinsho; 2005 Feb 15; 63(2):305-8. PubMed ID: 15714983
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.